CN1170851C

CN1170851C - Fatty diacylamino acid insulin as oral medicine for treating diabetes and its synthesizing process

Info

Publication number: CN1170851C
Application number: CNB011284986A
Authority: CN
Inventors: 黄开勋; 郭华; 徐辉碧; 高秋华; 陈泽宪
Original assignee: Huazhong University of Science and Technology
Current assignee: Huazhong University of Science and Technology
Priority date: 2001-09-27
Filing date: 2001-09-27
Publication date: 2004-10-13
Anticipated expiration: 2021-09-27
Also published as: CN1376717A

Abstract

The present invention relates to oral medicine for synthesizing and treating diabetes by a chemosynthetic method, namely that fatty diacylamino acid insulin is synthesized for the chemical modification of insulin. The compound has a general formula of insulin, OC(CH2)nCONHCHRCOOH, in the formula, the n is equal to 6 to 8, and the R is a side chain of several kinds of amino acid. The present invention also relates to a specific synthetic method of the compound, a specific synthetic method for decanedioyl glycin insulin of the compound, and the effect for reducing blood sugar thereof.

Description

Fatty diamido acid insulin as oral medicine for treating diabetes and its synthesis method

Technical Field

The invention belongs to a chemically synthesized medical drug, namely an oral drug for treating diabetes, which synthesizes fatty diamido acid insulin by chemically modifying insulin.

Technical Field

Diabetes is a common metabolic disease, and the incidence rate is on the rise at home and abroad. With the aging of the world population, diabetes has become a common disease and frequently encountered disease. According to incomplete statistics, more than 3000 people have diabetes patients in China, and the incidence rate of diabetes is up to 3.2%. Diabetes is the third leading cause of death in humans. Insulin is the most effective drug for the treatment of diabetes. However, insulin is a protein, and is easily degraded and inactivated by acid and various proteases in the gastrointestinal tract, so that the insulin cannot be directly orally taken and only can be injected for administration, which brings great pain and inconvenience to patients who need lifelong administration. Therefore, research and development of safe, convenient and effective non-injection insulin administration routes have become important issues of medicine world attention. There are many non-injection insulin routes, such as directly using insulin and some absorption enhancers to make oral, mucosal or cutaneous absorption of eye, nose, lung, rectum, or directly using insulin to wrap with liposome or polymer to make oral administration. Of these routes, direct oral administration is the simplest and accepted by patients. However, no success has been reported in these studies except for the important progress made in insulin oral spray (Chinese patent invention, patent No. 00114318.2). Even insulin oral sprays suffer from the disadvantages of increased bioavailability and inconvenient patient use. The development of oral insulin formulations is desired in the prior art by chemical modification of insulin. [ protein]was synthesized in patent EP 0511600A 2 to Kuraray Co., Ltd][Z]A derivative of n, whereinproteins are polypeptide proteins including insulin, [ Z]]is-CO-W-COOH, wherein W is a long-chain carbohydrate group which can contain heteroatoms. WO 95/07931, which is filed by Novo Nordisk A/S, and EP 0712861A 2 and EP 0712862A 2, which are both EliLilly and Company, respectively, also describe methods for the synthesis of chemically modified insulin. The invention aims to synthesize chemically modified insulin capable of resisting hydrolysis of intestinal trypsin for preparing direct oral insulin preparations, and is characterized in that chemically modified groups of the insulin contain amino acid residues and peptide bonds are introduced. Chemically modified insulin (insulin-OC (CH) according to the invention₂) nCONHCHRCOOH) has not been reported at present. The chemical modification group not only protects trypsin from attacking insulinThe site and the introduced peptide bond can compete with the site of trypsin for attacking insulin, so that the insulin is better protected from being hydrolyzed by the trypsin, and the effect of promoting the absorption of the insulin is achieved.

Disclosure of Invention

The key point of the invention isthat a group containing a peptide bond is covalently bonded at a proper position of the insulin by a chemical modification method to protect the trypsin from attacking the insulin, so that the insulin is prevented from being hydrolyzed by the trypsin. The chemical formula of the substance is as follows:

insulin-OC (CH)₂)nCONHCHRCOOH

Wherein n is 6-18; r is one of side chains of lysine, glycine, alanine, valine, leucine, isoleucine and phenylalanine.

The synthetic route is as follows:

or

Wherein X ═ F, Cl, Br, I; n is 6-18; r is one of side chains of lysine, glycine, alanine, valine, leucine, isoleucine and phenylalanine.

The synthesis method of the compound comprises the following steps: a, preparing a solution with pH7-11 by using sodium hydroxide, reacting with fatty acid dihalide, wherein the molar ratio of glycine to fatty acid dihalide is 1 to 1, stirring for 0.2-1 hour in ice bath to generate the fatty acid dihalide amino acid: XOC (CH)₂)nCONHCHRCOOH；

b, dissolving benzotriazole (50 g) in tert-butyl methyl ether (800-1000ml) solution containing triethylamine (40-60 g), keeping the temperature at 15-30 ℃, dropwise adding fatty diacid halide amino acid, wherein the molar ratio of benzotriazole to fatty diacid halide amino acid is 1: 1, transferring reaction precipitate by filtration, evaporating filtrate at 30-80 ℃ under reduced pressure to dryness, and recrystallizing residue with acetone to obtain fatty diacid halide amino acid benzotriazole:

benzotriazole-OC (CH)₂)nCONHCHRCOOH

c, dissolving insulin (0.8mmol) in a solution (0.2-0.6ml) of N-methyl-pyrrolidone (5-10ml) and triethylamine, simultaneously dissolving fatty diacylamino acid benzotriazole (1.2-2mmol) in a solution (1.5ml) of N-methyl-pyrrolidone, slowly adding the fatty diacylamino acid benzotriazole solution into the insulin solution, wherein the molar ratio of the fatty diacylamino acid benzotriazole to insulin is 1: 1-2: 1, stirring at 0-20 ℃ for 1-3 hours, adding acetone into the obtained reaction mixture until a precipitate is generated, centrifuging, removing a supernatant, and freeze-drying the precipitate to constant weight. The raw material medicine 'fatty diamido acid insulin' is prepared into enteric-coated tablets or enteric-coated capsules, namely the insulin oral medicine for treating diabetes.

Taking one of such compounds: sebacoyl glycine insulin (n ═ 8, R is the side chain of glycine) as an animal experiment, the results are as follows: sebacoyl glycinin insulin and insulin are respectively prepared into 5IU/ml phosphate buffer solution (pH is 7), 12 mice which are fasted for 18 hours are taken, divided into three groups (two sebacoyl glycinin groups and insulin groups respectively), 0.15 ml/mouse is injected subcutaneously respectively, blood samples are taken from tail veins to measure blood sugar, the blood samples are taken every 40 minutes until 2 hours, and the blood sugar values at different times are measured. As shown in FIG. 2, the results demonstrated that sebacoyl glycine insulin has no difference in its hypoglycemic effect from insulin. A certain amount of trypsin is respectively added into a sebacoyl glycine insulin and an insulin phosphate buffer solution (5IU/ml), after the mixture is kept at 37℃ for 8 hours, mice which are fasted for 12 hours and randomly divided into three groups (two sebacoyl glycine insulin groups and 6 insulin groups, each group) are respectively injected with 0.15 ml/mouse of sebacoyl glycine insulin and insulin phosphate buffer solution, and the blood glucose value of the mice after injection is measured for 0 to 160min, so that the results are shown in a graph 3, insulin has no hypoglycemic effect due to the hydrolysis of the trypsin, and the sebacoyl glycine insulin still keeps good biological activity, and the sebacoyl glycine insulin has good anti-trypsin degradation capability.

Description of the drawings:

FIG. 1 RP-HPLC graph of sebacoyl glycinate insulin comparing the hypoglycemic capacity of insulin and sebacoyl glycinate insulin in FIG. 2 with time (min) on the abscissa and blood glucose level (mmol/l) on the ordinate, ■ insulin, ● modified insulin-1, ▲ modified insulin-2, FIG. 3 comparing the anti-trypsin degradation of insulin and sebacoyl glycinate insulin with time (min) on the abscissa and blood glucose level (mmol/l) ■ insulin, ● modified insulin-2, ▲ modified insulin-1.

Detailed Description

Examples are: synthesis of sebacoyl glycine insulin (n ═ 8, R is the side chain of glycine)

Reaction of sebacic acid with thionyl chloride to yield sebacoyl chloride (ClOC (CH)₂)₈COCl), dissolving glycine in sodium hydroxide solution, reacting with sebacoyl chloride (molar ratio of 1: 1), stirring for 0.5 hr in ice bathDecanoyl chloroglycine (ClOC (CH)₂)₈CONHCH₂COOH). Dissolving benzotriazole in tert-butyl methyl ether and triethylamine, maintaining temperature at 20-30 deg.C, adding dropwise sebacoyl chloride glycine, transferring reaction precipitate by filtration, evaporating filtrate at 60 deg.C under reduced pressure to dryness, and recrystallizing residue with acetone to obtain sebacoyl glycine benzotriazole (benzotriazole-OC (CH)₂)₈CONHCH₂COOH). Dissolving insulin in N-methyl-pyrrolidone and triethylamine solution, and dissolving sebacoyl glycine benzotriazole in N-methyl-pyrrolidoneAdding appropriate amount of sebacoyl glycine benzotriazole solution into the above insulin solution, stirring in ice bath for 2-3 hr to obtain reaction mixture, adding acetone until precipitate is formed, centrifuging, removing supernatant, freeze drying the precipitate to constant weight to obtain chemically modified insulin-sebacoyl glycine insulin (insulin-OC (CH)₂)₈CONHCH₂COOH), yield was 89%. The synthetic route is as follows:

the retention time of the sebacoyl glycine insulin is identified by adopting RP-HPLC, and the result shows that in an RP-HPLC map (as shown in figure 1), the area of a main peak with the retention time of 3.96min accounts for 96.6%, a secondary peak with the retention time of 4.72min accounts for 3.4%, the retention time of the single pure insulin under the same condition is 4.71min, and the main peak with the retention time of 3.96min is sebacoyl glycine insulin.

Claims

1. A medicine for treating diabetes is a compound fatty diamido acid insulin, and the chemical general formula of the compound is as follows: pancreas (pancreas)islandin-OC (CH)₂)nCONHCHRCOOH；

Wherein n is 6-18; r is: lysine, glycine, alanine, valine, leucine, isoleucine, phenylalanine.

2. The medicament for treating diabetes according to claim 1, which is an oral medicament for treating diabetes.

3. A process for preparing the product of claim 1, comprising the steps of: a, preparing a solution with pH value of 7-11 by using sodium hydroxide, reacting with fatty diacid halide, wherein the molar ratio of the amino acid to the fatty diacid halide is 1: 1, stirring for 0.2-1 hour in ice bath to generate the fatty diacid halide amino acid: XOC (CH)₂)nCONHCHRCOOH；

b, dissolving 50 g of benzotriazole in 1000ml of tertiary butyl methyl ether 800-containing solution containing 40-60 g of triethylamine, keeping the temperature at 15-30 ℃, dropwise adding fatty diacid halide amino acid, wherein the molar ratio of benzotriazole to fatty diacid halide amino acid is 1: 1, transferring reaction precipitates through filtration, evaporating filtrate at 30-80 ℃ under reduced pressure to dryness, and recrystallizing residues with acetone to obtain the fatty diacid halide amino acid benzotriazole: benzotriazole-OC (CH)₂)nCONHCHRCOOH；

c, dissolving 0.8mmol of insulin in 5-10ml of N-methyl-pyrrolidone and 0.2-0.6ml of triethylamine solution, simultaneously dissolving 1.2-2mmol of aliphatic diacylamino acid benzotriazole in 1.5ml of N-methyl-pyrrolidone solution, slowly adding the aliphatic diacylamino acid benzotriazole solution into the insulin solution, wherein the molar ratio of the aliphatic diacylamino acid benzotriazole to the insulin is 1: 1-2: 1, stirring for 1-3hours at 0-20 ℃, adding acetone into the obtained reaction mixture until precipitates are generated, centrifuging, removing a supernatant, and freeze-drying the precipitates to constant weight.